 | | Vol. 13.33 – 25 August, 2022 |
| |
|
|
| In arthritis, ETS1 drove polarization toward tissue-destructive fibroblasts by orchestrating hitherto undescribed regulatory elements of the osteoclast differentiation factor receptor activator of nuclear factor-κB ligand as well as matrix metalloproteinases.
[Nature Immunology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers dissected the role of SOX9-mediated cancer stemness attributes and immunosuppressive microenvironment in advanced gastric adenocarcinoma for novel therapeutic discoveries.
[Gut] |
|
|
|
| The authors fabricated bioactive scaffolds through strontium incorporation based on our previously developed modified amino-functional mesoporous bioactive glass and systematically investigated the bioactivity of the resulting scaffold in vitro and in vivo in an osteoporotic rat model.
[Bone Research] |
|
|
|
| Intelligent copper-dropped calcium carbonate (Cu/CaCO3) loading sonosensitizer Ce6 nanoparticles were established to realize tumor microenvironment-responsive self-supply of oxygen and successively Ca2+-overloading-strengthened chemodynamic therapy/sonodynamic therapy.
[Small] |
|
|
|
| Scientists identified Delta/Notch signaling in subperineurial glia, a crucial glial type for Drosophila motor axon ensheathment and the blood–brain barrier, to be essential for controlling the expression of matrix metalloproteinase 1, a major regulator of the ECM.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers developed a dual stem cell approach for effective vascular regeneration by utilizing two distinct types of stem cells that continuously secreted stromal-derived factor-1α to simultaneously promote natal vasculogenesis and angiogenesis.
[Experimental & Molecular Medicine] |
|
|
|
| The authors reported for the first time that TGF‐β1/Smad3 could promote liver fibrosis by upregulating UCA1, which further affected DKK1 and collagen, such as COL1A1, COL1A2, and COL3A1.
[Journal of Molecular Medicine] |
|
|
|
| Investigators proposed an automated uni-/bi-directional perfusion bioreactor combinable with pulsed electromagnetic field stimulation for culturing 3D bone tissue models.
[Scientific Reports] |
|
|
|
| The authors investigated, using an in vitro hyperglycaemia bone tissue engineering model, the differing effects of glucose levels, hypoxia, and chemicals known to stabilize HIF-1α on bone formation.
[Scientific Reports] |
|
|
|
| Scientists demonstrated that the noncanonical Wnt receptor, Ror2, regulated tumor cell-driven matrix remodeling and invasion in breast cancer.
[Molecular Biology of the Cell] |
|
|
|
| Investigators conducted skin regeneration in a rat model of full-thickness dermal wound by transplanting genetically modified mesenchymal stem cells seeded on a 3D collagen scaffold.
[Journal of the Royal Society interface] |
|
|
|
| A complex combination of the simulated ECM was examined with a comprehensive analysis of cell response and a variety of controls.
[Biomedical Materials] |
|
|
|
|
| The authors identify the challenges impeding translation of strategies and technologies for cell-based cartilage repair, such as the disconnect between university funding and regulatory requirements.
[Science Translational Medicine] |
|
|
|
| Advances in heterogeneous cell coculture systems using semi-permeable membranes have made it feasible to create in vivo-like microenvironments for a myriad of biomedical applications.
[Trends in Biotechnology] |
|
|
|
| Scientists discuss the considerations for chiral supramolecular hydrogel design, as well as the influence of external stimuli on chiral hydrogel construction.
[Wiley interdisciplinary Reviews-Nanomedicine and Nanobiotechnology] |
|
|
|
|
| Alume Biosciences, Inc. announced that the first patient has been dosed in a Phase III pivotal study of ALM-488, a peptide-dye conjugate that binds to the ECM of nerves, allowing real-time nerve illumination during surgery.
[Alume Biosciences (Cision US, Inc.)] |
|
|
|
| Regen BioPharma, Inc. announced the development of a novel immunotherapy for treatment of solid tumors. The current approach developed by the company involves initial treatment of the tumor microenvironment with cells of the innate immune system called CAR-M and CAR-NK cells.
[Regen BioPharma, Inc. (Cision US, Inc.)] |
|
|
|
|
| 7 – 8 November 2022
London, England, United Kingdom |
|
|
|
|
|
| | Stanford Medicine – Stanford, California, United States |
|
|
|
| | Darmstadt University of Technology – Darmstadt, Germany |
|
|
|
| | National Research Council Canada – Toronto, Ontario, Canada |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Yale University – New Haven, Connecticut, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
